Composition for prophylaxis or treatment of il-8 related diseases

Patent metadata

Field	Value
Publication number	US-2019169286-A1
Application number	US-201716323142-A
Country	US
Kind code	A1
Filing date	Aug 4, 2017
Priority date	Aug 5, 2016
Publication date	Jun 6, 2019
Grant date	—

Abstract

For example, therapeutic methods and the like for novel IL-8-related diseases using an IL-8 signal inhibitor are provided. Alternatively, for example, therapeutic methods and the like for known or novel IL-8-related diseases using a novel anti-IL-8 antibody are provided.

First claim

1 . A composition for treating or preventing an IL-8-related disease, which comprises as an active ingredient an isolated anti-IL-8 antibody that binds to human IL-8, wherein the IL-8-related disease is selected from the group consisting of:
endometriosis; adenomyosis; dysmenorrhea; adhesion; fibrotic diseases; pain in endometriosis, adenomyosis, or dysmenorrhea; infertility; and pain resulting from adhesion, fibrosis, or inflammation; wherein the anti-IL-8 antibody is selected from the group consisting of:
(1) an anti-IL-8 antibody which binds to IL-8 in a pH-dependent manner, and comprises at least one amino acid substitution in at least one of:
(a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 23,
(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 24,
(c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 25,
(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 26,
(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 27, and
(f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 28;

(2) an anti-IL-8 antibody which binds to IL-8 in a pH-dependent manner, and comprises at least one amino acid substitution in at least one of:
(a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 23,
(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 24,
(c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 25,
(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 26,
(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 27, and
(f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 28,

 wherein the anti-IL-8 antibody at least comprises amino acid substitutions of:
 tyrosine at position 3 in the amino acid sequence of SEQ ID NO: 25, asparagine at position 1 and leucine at position 5 in the amino acid sequence of SEQ ID NO: 27, and glutamine at position 1 in the amino acid sequence of SEQ ID NO: 28;
(3) an anti-IL-8 antibody which binds to IL-8 in a pH-dependent manner, and comprises at least one amino acid substitution in at least one of:
(a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 23,
(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 24,
(c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 25,
(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 26,
(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 27, and
(f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 28,

 wherein the anti-IL-8 antibody at least comprises amino acid substitutions of:
 tyrosine at position 9 and arginine at position 11 in the amino acid sequence of SEQ ID NO: 24, and tyrosine at position 3 in the amino acid sequence of SEQ ID NO: 25;
(4) an anti-IL-8 antibody which binds to IL-8 in a pH-dependent manner, and comprises at least one amino acid substitution in at least one of:
(a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 23,
(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 24,
(c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 25,
(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 26,
(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 27, and
(f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 28,

 wherein the anti-IL-8 antibody at least comprises amino acid substitutions of:
 alanine at position 6, glycine at position 8, tyrosine at position 9, and arginine at position 11 in the amino acid sequence of SEQ ID NO: 24, and
 tyrosine at position 3 in the amino acid sequence of SEQ ID NO: 25;
(5) an anti-IL-8 antibody which binds to IL-8 in a pH-dependent manner, and comprises at least one amino acid substitution in at least one of:
(a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 23,
(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 24,
(c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 25,
(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 26,
(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 27, and
(f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 28,

 wherein the anti-IL-8 antibody at least comprises amino acid substitutions of:
 asparagine at position 1 and leucine at position 5 in the amino acid sequence of SEQ ID NO: 27, and glutamine at position 1 in the amino acid sequence of SEQ ID NO: 28;
(6) an anti-IL-8 antibody which binds to IL-8 in a pH-dependent manner, and comprises at least one amino acid substitution in at least one of:
(a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 23,
(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 24,
(c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 25,
(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 26,
(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 27, and
(f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 28,

 wherein the anti-IL-8 antibody at least comprises amino acid substitutions of: tyrosine at position 9 and arginine at position 11 in the amino acid sequence of SEQ ID NO: 24, tyrosine at position 3 in the amino acid sequence of SEQ ID NO: 25, asparagine at position 1 and leucine at position 5 in the amino acid sequence of SEQ ID NO: 27, and glutamine at position 1 in the amino acid sequence of SEQ ID NO: 28; and
(7) an anti-IL-8 antibody which binds to IL-8 in a pH-dependent manner, and comprises at least one amino acid substitution in at least one of:
(a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 23,
(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 24,
(c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 25,
(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 26,
(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 27, and
(f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 28,

 wherein the anti-IL-8 antibody at least comprises amino acid substitutions of:
 alanine at position 6, glycine at position 8, tyrosine at position 9, and arginine at position 11 in the amino acid sequence of SEQ ID NO: 24, tyrosine at position 3 in the amino acid sequence of SEQ ID NO: 25, asparagine at position 1 and leucine at position 5 in the amino acid sequence of SEQ ID NO: 27, and glutamine at position 1 in the amino acid sequence of SEQ ID NO: 28.

2 . The composition of claim 1 , wherein the anti-IL-8 antibody is selected from the group consisting of:
(8) the anti-IL-8 antibody of any one of (1) to (7) of claim 1 , which comprises:
(a) the amino acid sequence of SEQ ID NO: 23 as HVR-H1,
(b) the amino acid sequence of SEQ ID NO: 29 as HVR-H2, and
(c) the amino acid sequence of SEQ ID NO: 30 as HVR-H3;
(9) the anti-IL-8 antibody of any one of (1) to (7) of claim 1 , which comprises:
(d) the amino acid sequence of SEQ ID NO: 26 as HVR-L1,
(e) the amino acid sequence of SEQ ID NO: 31 as HVR-L2, and
(f) the amino acid sequence of SEQ ID NO: 32 as HVR-L3;
(10) the anti-IL-8 antibody of any one of (1) to (7) of claim 1 , which comprises:
(a) the amino acid sequence of SEQ ID NO: 23 as HVR-H1,
(b) the amino acid sequence of SEQ ID NO: 24 as HVR-H2, and
(c) the amino acid sequence of SEQ ID NO: 30 as HVR-H3;
(11) the anti-IL-8 antibody of any one of (1) to (7) of claim 1 , which comprises:
(d) the amino acid sequence of SEQ ID NO: 26 as HVR-L1,
(e) the amino acid sequence of SEQ ID NO: 107 as HVR-L2, and
(f) the amino acid sequence of SEQ ID NO: 32 as HVR-L3;
(12) the anti-IL-8 antibody of any one of (1) to (7) of claim 1 , which comprises:
(a) the amino acid sequence of SEQ ID NO: 23 as HVR-H1,
(b) the amino acid sequence of SEQ ID NO: 29 as HVR-H2,
(c) the amino acid sequence of SEQ ID NO: 30 as HVR-H3,
(d) the amino acid sequence of SEQ ID NO: 26 as HVR-L1,
(e) the amino acid sequence of SEQ ID NO: 31 as HVR-L2, and
(f) the amino acid sequence of SEQ ID NO: 32 as HVR-L3;
(13) the anti-I

Assignees

• Chugai Pharmaceutical Co Ltd
• Univ Jichi Medical
• Nat Inst Biomedical Innovation Health & Nutrition

Inventors

• Kakiuchi Ayako
• Kato Atsuhiko
• Hayashi Shuji
• Yanagisawa Izumi
• Konno Ryo
• Netsu Sachiho
• Sankai Tadashi

Classifications

• C07K2317/90

  characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• C07K2317/52

  Constant or Fc region; Isotype · CPC title